MTOR and hepatocellular carcinoma: Because mTOR activation is involved in KrasG12D mutation and Tscl insufficiency-driven HCC, we investigated the therapeutic effect of the mTOR inhibitors rapamycin and sapanisertib (a new selective inhibitor of mTORC1/2) on hepatocarcinogenesis triggered by mutant Kras and Tscl insufficiency.